Skip to content

Elacestrant

Published: July 26, 2026Updated: July 26, 2026

Elacestrant is an oral selective estrogen receptor degrader (SERD) used for the treatment of postmenopausal women and adult men with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer who have progressed following prior endocrine therapy. The medication works by binding to estrogen receptor-alpha (ERα) and inducing its degradation, thereby blocking the estrogen signaling pathway that drives tumor growth in ER+ breast cancer.

Quick summary

Elacestrant is an estrogen receptor antagonist used to treat ER+/HER2- advanced breast cancer that has progressed on prior endocrine therapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

ATC
L02BA04
RxNorm
2628469
Generic
Elacestrant
Class
atc-l02
Brands
Orserdu
Availability
rx
Lactation
unknown
Routes
oral
Forms
tablet
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Treatment of ER+/HER2- advanced or metastatic breast cancer in adults with disease progression following at least one line of endocrine therapy. Approved specifically for postmenopausal women and adult men.

Elacestrant is a selective estrogen receptor degrader (SERD) that selectively binds to estrogen receptor-alpha (ERα), inducing its degradation. By blocking and degrading ERα, it inhibits 17β-estradiol mediated cell proliferation in ER+ breast cancer cells, preventing estrogen-driven tumor growth.

As an oral medication, elacestrant offers a less invasive alternative to injectable SERDs. Common side effects may include musculoskeletal pain, nausea, and fatigue. Patients should be monitored for hepatotoxicity and thromboembolic events. Use with caution in patients with known hepatic impairment.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy